Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation

医学 奥马佐单抗 中止 慢性荨麻疹 皮肤病科 药品 梅德林 跨国公司 重症监护医学 内科学 药理学 免疫学 免疫球蛋白E 抗体 政治学 法学
作者
Reineke Soegiharto,Mehran Alizadeh Aghdam,Jennifer Astrup Sørensen,Esmee van Lindonk,Ferhan Bulut Demir,Nasser Mohammad Porras,Yoshimi Matsuo,Lea Kiefer,André C. Knulst,Marcus Maurer,Carla Ritchie,Michael Rudenko,Emek Kocatürk,Roberta Fachini Jardim Criado,Stamatios Gregoriou,Tatjana Bobylev,Andreas Kleinheinz,Shunsuke Takahagi,Michihiro Hide,Ana M. Giménez‐Arnau
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:160 (9): 927-927 被引量:5
标识
DOI:10.1001/jamadermatol.2024.2056
摘要

Importance Treating patients with chronic urticaria using omalizumab has been shown to be safe and effective in randomized clinical trials. Multinational studies on long-term omalizumab performance in chronic urticaria in clinical practice settings are lacking, especially on drug survival. Drug survival, which refers to the length of time that patients are treated with a specific drug, is a comprehensive outcome covering effectiveness, safety, and patient and physician preferences. Furthermore, little is known about the reasons and potential predictors for omalizumab discontinuation. Objective To investigate omalizumab drug survival as well as reasons and potential predictors for discontinuation in a large, diverse population. Design, Setting, and Participants This international multicenter cohort study was conducted at 14 Urticaria Centers of Reference and Excellence in 10 countries, including all patients with chronic urticaria from these centers who were ever treated with omalizumab. Main Outcomes and Measures Drug survival analysis was performed to assess time to discontinuation. Patient characteristics and treatment protocols were investigated by Cox regression analysis to identify potential predictors for omalizumab discontinuation. Results In 2325 patients with chronic urticaria who started omalizumab between June 2009 and July 2022, the mean (SD) age of the cohort was 42 (6) years, and 1650 participants (71%) were female. Overall omalizumab survival rates decreased from 76% to 39% after 1 to 7 years, respectively (median survival time, 3.3 [95 % CI, 2.9-4.0] years), primarily due to discontinuation from well-controlled disease in 576 patients (65%). Ineffectiveness and adverse effects were reasons for discontinuation in a far smaller proportion of patients, totaling 164 patients (18%) and 31 patients (4%), respectively. Fast treatment response was associated with higher rates of omalizumab discontinuation due to well-controlled disease (hazard ratio, 1.45 [95% CI, 1.20-1.75]), and disease duration of more than 2 years was associated with lower rates of discontinuation due to well-controlled disease (HR, 0.81 [95% CI, 0.67-0.98]). Immunosuppressive cotreatment at the start of omalizumab and autoimmune disease was associated with a higher risk for discontinuation due to ineffectiveness (HR, 1.65 [95% CI, 1.12-2.42]). The presence of spontaneous wheals (HR, 0.62 [95% CI, 0.41-0.93]) and access to higher dosages (HR, 0.40 [95% CI, 0.27-0.58) were both associated with a lower risk for discontinuation of omalizumab due to ineffectiveness. Conclusion and Relevance This multinational omalizumab drug survival cohort study demonstrated that treatment of chronic urticaria with omalizumab in a clinical setting is effective and safe, and well-controlled disease is the main reason for treatment discontinuation. These findings on omalizumab drug survival rates and reasons and potential predictors for discontinuation may guide patients and physicians in clinical decision-making and expectation management. These results may call for the identification of biomarkers for chronic urticaria remission in complete responders to omalizumab treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
luckweb完成签到,获得积分10
3秒前
猫的毛完成签到 ,获得积分10
4秒前
nicky完成签到 ,获得积分10
5秒前
麦子完成签到 ,获得积分10
6秒前
6秒前
Wilson完成签到 ,获得积分10
7秒前
luckweb发布了新的文献求助10
7秒前
7秒前
11秒前
14秒前
传奇3应助wujiwuhui采纳,获得10
16秒前
开心寄松完成签到,获得积分10
18秒前
北宫完成签到 ,获得积分10
18秒前
wansida完成签到,获得积分10
22秒前
QXS完成签到 ,获得积分10
22秒前
23秒前
菠萝完成签到 ,获得积分10
23秒前
领导范儿应助Villanellel采纳,获得10
27秒前
wintersss完成签到,获得积分10
27秒前
尹尹发布了新的文献求助10
28秒前
量子星尘发布了新的文献求助10
30秒前
zzzzzz完成签到 ,获得积分10
34秒前
坦率的枕头完成签到,获得积分10
34秒前
XS_QI完成签到 ,获得积分10
34秒前
与共发布了新的文献求助10
37秒前
苑阿宇完成签到 ,获得积分10
37秒前
yck1027完成签到,获得积分10
38秒前
fatcat完成签到,获得积分10
38秒前
斯文败类应助Camus采纳,获得10
39秒前
41秒前
Tammy完成签到 ,获得积分10
41秒前
Herisland完成签到 ,获得积分10
43秒前
lulalula完成签到,获得积分10
44秒前
NEO完成签到 ,获得积分10
46秒前
zcydbttj2011完成签到 ,获得积分10
48秒前
温暖的小鸭子完成签到,获得积分10
50秒前
54秒前
王泽厚发布了新的文献求助20
55秒前
雪花发布了新的文献求助10
57秒前
周全完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022